x
The holding company benefited from the good performance of the stock market in the first nine months of its financial year.
(AWP) The investment company HBM Healthcare (HBMN 241 2.12%) Investments (HBM) achieved a profit of CHF 265.7 million in the first nine months of the 2019/20 financial year that started in April. The good development on the stock exchanges contributed significantly to the good performance, the company said on Friday.
Compared to the profit of CHF 81 million in the previous year, the value has more than tripled. For the third quarter, the company put the profit at CHF 163.2 million.
The share price has also developed positively so far: this rose by 36.3%, while the intrinsic value (NAV) of the share only increased by 20.2%.
Above all, the strong performance in the third quarter was thanks to the price gains of listed investments. For example, the listed investments in HBM Healthcare Investments' portfolio saw an increase in value of CHF 223 million in the third business quarter of the group. Around a third of these were former private companies, all of which have been listed on the stock exchange in the past fifteen months and have been a good one since then Would have shown performance.
According to the announcement, the private portfolio was further strengthened with a new investment in Arcutis Biotherapeutics and various follow-up financing.
HBM is optimistic for the current calendar year, "because many portfolio companies have important IPOs, admission decisions and research publications, each with considerable potential for increasing value," as the message said. But acquisitions are also likely to continue to play an important role in the health sector and, in one case or another, bring added value.
